Ballentine Partners, LLC Cure Vac N.V. Transaction History
Ballentine Partners, LLC
- $5.81 Billion
- Q3 2024
A detailed history of Ballentine Partners, LLC transactions in Cure Vac N.V. stock. As of the latest transaction made, Ballentine Partners, LLC holds 22,755 shares of CVAC stock, worth $70,995. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,755
Previous 14,349
58.58%
Holding current value
$70,995
Previous $48,000
37.5%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CVAC
# of Institutions
93Shares Held
12.3MCall Options Held
164KPut Options Held
117K-
Israel Englander Millennium Management LLC | New York, Ny2.42MShares$7.54 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.25MShares$7.03 Million0.0% of portfolio
-
Bill & Melinda Gates Foundation Seattle, WA1.57MShares$4.89 Million10.6% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.01MShares$3.16 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct780KShares$2.43 Million0.01% of portfolio
About CureVac N.V.
- Ticker CVAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,467,008
- Market Cap $585M
- Description
- CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...